Nephrocare Health Services Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
NEPHROPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.3 pts less than Nifty Microcap 250 and 5.7 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Nephrocare Health Services reported standalone FY26 revenue of ₹6,297 million, up 15.8% from ₹5,436 million in FY25. However, the company posted a net loss of ₹80.6 million for FY26 compared to a profit of ₹342.4 million in FY25. Q4 FY26 showed strong recovery with revenue of ₹1,643 million and profit of ₹109 million. Finance costs nearly quadrupled to ₹498 million due to a ₹372 million non-cash FVTPL interest charge. Allowance for expected credit losses jumped over 5x to ₹133 million from ₹26 million, indicating stress on receivables. The company listed on NSE and BSE via IPO in December 2025, raising approximately ₹3,902 million net. The Board also approved ₹10 crore investment in Nepal subsidiary and ₹140 crore total collateral support (₹70 crore each) for Singapore and Saudi Arabia subsidiaries.
The swing to annual loss despite Q4 profitability raises concerns about recurring profitability; the surge in credit losses and finance costs warrants monitoring. The substantial subsidiary guarantees increase exposure to overseas operations.